&Partners’s Charles River Laboratories CRL Stock Holding History

&Partners’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$661K	Buy	3,833 +371	+11%	+$68.8K	﹤0.01%	1540
2025 Q4	$689K	Buy	3,462 +312	+10%	+$56.6K	﹤0.01%	1442
2025 Q3	$488K	Sell	3,150 -790	-20%	-$125K	﹤0.01%	1459
2025 Q2	$598K	Sell	3,940 -4,805	-55%	-$641K	﹤0.01%	1263
2025 Q1	$1.36M	Buy	8,745 +1,128	+15%	+$189K	0.01%	702
2024 Q4	$1.42M	Buy	7,617 +1,614	+27%	+$311K	0.02%	622
2024 Q3	$1.18M	Buy	6,003 +2,708	+82%	+$563K	0.02%	507
2024 Q2	$681K	Buy	+3,295	New	+$747K	0.03%	443

Other funds holding CRL

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

&Partners's CRL Position: Q1 2026 in Review

&Partners increased its Charles River Laboratories (CRL) stake by 11% in Q1 2026, buying an estimated $68.8K and bringing the position to 3,833 shares worth $661K. The position accounts for ﹤0.01% of the portfolio, ranked #1540.

&Partners first reported a position in CRL in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.42M in Q4 2024. 557 funds tracked by Wall St. Rank hold CRL as of Q1 2026.

&Partners held 3,833 shares of Charles River Laboratories worth $661K as of Q1 2026.
&Partners bought 371 Charles River Laboratories shares in Q1 2026, an estimated $68.8K.
Charles River Laboratories made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #1540 holding.
&Partners first reported a position in Charles River Laboratories in Q2 2024 and has held it in 8 quarters since.
&Partners's Charles River Laboratories position peaked at $1.42M in Q4 2024.
557 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.